Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Mol Pharm ; 12(6): 1813-35, 2015 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-25635711

RESUMO

Antibody-drug conjugates (ADCs) that are currently on the market or in clinical trials are predominantly based on two drug classes: auristatins and maytansinoids. Both are tubulin binders and block the cell in its progression through mitosis. We set out to develop a new class of linker-drugs based on duocarmycins, potent DNA-alkylating agents that are composed of a DNA-alkylating and a DNA-binding moiety and that bind into the minor groove of DNA. Linker-drugs were evaluated as ADCs by conjugation to the anti-HER2 antibody trastuzumab via reduced interchain disulfides. Duocarmycin 3b, bearing an imidazo[1,2-a]pyridine-based DNA-binding unit, was selected as the drug moiety, notably because of its rapid degradation in plasma. The drug was incorporated into the linker-drugs in its inactive prodrug form, seco-duocarmycin 3a. Linker attachment to the hydroxyl group in the DNA-alkylating moiety was favored over linking to the DNA-binding moiety, as the first approach gave more consistent results for in vitro cytotoxicity and generated ADCs with excellent human plasma stability. Linker-drug 2 was eventually selected based on the properties of the corresponding trastuzumab conjugate, SYD983, which had an average drug-to-antibody ratio (DAR) of about 2. SYD983 showed subnanomolar potencies against multiple human cancer cell lines, was highly efficacious in a BT-474 xenograft model, and had a long half-life in cynomolgus monkeys, in line with high stability in monkey and human plasma. Studies comparing ADCs with a different average DAR showed that a higher average DAR leads to increased efficacy but also to somewhat less favorable physicochemical and toxicological properties. Fractionation of SYD983 with hydrophobic interaction chromatography resulted in SYD985, consisting of about 95% DAR2 and DAR4 species in an approximate 2:1 ratio and having an average DAR of about 2.8. SYD985 combines several favorable properties from the unfractionated ADCs with an improved homogeneity. It was selected for further development and recently entered clinical Phase I evaluation.


Assuntos
Imunoconjugados/química , Indóis/química , Receptor ErbB-2/metabolismo , Antineoplásicos/química , Antineoplásicos/farmacocinética , Linhagem Celular Tumoral , Duocarmicinas , Humanos , Imunoconjugados/farmacocinética , Pirrolidinonas/química
2.
Regul Toxicol Pharmacol ; 67(3): 351-9, 2013 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-23978386

RESUMO

Hydroxypropyl-ß-cyclodextrin (HPßCD) is a complexation agent used to enhance drug solubilization and formulation stability. Although its toxicity is well characterized, its cardiovascular effects are less known. To investigate them, HPßCD was infused intravenously over 10 min in anesthetized dogs (10-40% (w/v, i.e. 200-800 mg/kg) in non-denervated animals and at 40% in denervated animals). HPßCD increased renal arteriolar resistance and decreased renal blood flow at all doses, almost immediately after infusion start, more drastically in females. A less pronounced increase in total peripheral resistance occurred in females only due to sex difference in sympathetic tone. Pulmonary hemodynamic parameters remained unaffected, suggesting that the renal effect was rather selective. As a consequence of the increased systemic blood pressure, heart rate decreased in normal animals without direct effect on cardiac conductance. This effect was abolished in denervated animals. This suggests that autonomous nervous feedback loops are functional in normal animals and that HPßCD has no direct chronotropic effect. In conclusion, systemic and renal hemodynamic changes should be considered as potential background effects at 200-400 mg/kg. At higher doses (800 mg/kg), changes are more pronounced and could mask/exacerbate hemodynamic response of drug candidate; such doses should be avoided in nonclinical safety studies.


Assuntos
Anestesia , Excipientes/efeitos adversos , Hemodinâmica/efeitos dos fármacos , Rim/efeitos dos fármacos , beta-Ciclodextrinas/efeitos adversos , 2-Hidroxipropil-beta-Ciclodextrina , Animais , Pressão Sanguínea/efeitos dos fármacos , Denervação , Cães , Relação Dose-Resposta a Droga , Avaliação Pré-Clínica de Medicamentos , Excipientes/administração & dosagem , Feminino , Sistema de Condução Cardíaco/efeitos dos fármacos , Frequência Cardíaca/efeitos dos fármacos , Infusões Intravenosas , Rim/irrigação sanguínea , Rim/inervação , Pulmão/irrigação sanguínea , Pulmão/efeitos dos fármacos , Pulmão/inervação , Masculino , Caracteres Sexuais , beta-Ciclodextrinas/administração & dosagem , beta-Ciclodextrinas/sangue
3.
Int J Pharm ; 413(1-2): 134-9, 2011 Jul 15.
Artigo em Inglês | MEDLINE | ID: mdl-21539905

RESUMO

Sugammadex, a thiolated γCD derivative used as an antagonist of steroidal blockers, was studied with regard to its tendency to self-associate in aqueous solution. Three independent methods - permeation through semi-permeable cellophane membranes, dynamic light scattering, and sedimentation equilibrium analytical ultracentrifugation - were used for this purpose. The results were in agreement with each other and showed no evidence of self-association in a wide sugammadex concentration range from 0.25 to 100mg/ml.


Assuntos
gama-Ciclodextrinas/química , Celofane/química , Relação Dose-Resposta a Droga , Bloqueadores Neuromusculares/antagonistas & inibidores , Soluções Farmacêuticas/química , Soluções/química , Sugammadex , Fatores de Tempo , Ultracentrifugação/métodos , gama-Ciclodextrinas/análise
4.
Arch Toxicol ; 82(5): 333-8, 2008 May.
Artigo em Inglês | MEDLINE | ID: mdl-17992515

RESUMO

A concept relating the lipophilicity of chemicals with their genotoxicity on a chromosomal level had been generated by Schultz and Onfelt (Chem Biol Interact 126:97-123, 2000). It was shown that aneuploidy in Chinese hamster V79 cells was elicited by lipophilic chemicals at concentrations related to their hydrophobicity (log P), whereas toxicants with a specific mode of action acted at concentrations consistently lower than predicted based on log P. We have now combined available data sets on aneuploidy/micronucleus formation with procedures used in QSAR modelling, in order to find new molecular descriptors for modelling non-specific chromosomal genotoxicity, and to optimise combinations thereof. Molecular structures of 26 chemicals, including steroids, were converted into single 3D models using Corina (version 3.20), and 11 descriptors of molecular properties were calculated. The data of 16 compounds assigned to a non-specific mode of action were imported into the QSAR module of the software package Cerius(2) (version 4.10). Applying genetic function approximation (GFA), linear equations were set up relating molecular descriptors with experimental concentrations at which doubling of micronuclei occurred in V79 cells (exp -log C). The number of variables (molecular descriptors) was limited to a maximum of three, and linear and quadratic terms were allowed. Based on the descriptions provided by the GFA procedure, log P was the most suitable single property to describe non-specific genotoxicity [r (2 ) = 0.88], confirming the original concept of Schultz and Onfelt. Using more descriptors (up to three in combination) resulted in an optimization of correlations up to r (2 )= 0.97. Such optimal correlation coefficients were obtained by combinations (a) of the numbers of hydrogen bond acceptors, the polar surface and total surface areas of molecules on one hand, and by (b) the dipole moment, polar surface and total surface descriptors on the other hand. In essence, the relation of polar surface to the total molecular surface appears pivotal to determine the non-specific chromosomal genotoxicity of lipophilic compounds.


Assuntos
Interações Hidrofóbicas e Hidrofílicas , Modelos Químicos , Mutagênicos/química , Mutagênicos/toxicidade , Animais , Linhagem Celular , Cromossomos de Mamíferos/efeitos dos fármacos , Cricetinae , Cricetulus , Testes para Micronúcleos , Estrutura Molecular , Relação Quantitativa Estrutura-Atividade
5.
Toxicol Pathol ; 33(6): 720-5, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-16263697

RESUMO

As part of regulatory safety testing program, a 13-week oral toxicity study with a new antipsychotic drug candidate was performed in beagle dogs. During this study, dark red/brown feces were recorded in treated dogs and increases in liver parameters (alanine aminotransferase, alkaline phosphatase, bilirubin) were measured biochemically. At the end of the study, livers of high-dose (50 mg/kg) animals were (mottled) dark brown, sometimes with pale foci. Histopathological examination of these livers showed dark globular pigment deposits in the hepatocellular cytoplasm and within the bile canaliculi. Varying numbers of inflammatory cell infiltrates were additionally present in association with the deposits. These pigment deposits showed birefringency with characteristic "Maltese Cross"-like structures under polarized light. Electronmicroscopy revealed the typical, so-called "sunburst" pattern with radiating double-lined crystalline structures. These morphologic characteristics strongly indicated at the presence of porphyrins, which was definitely confirmed biochemically. Published reports of drug-induced hepatic porphyria in dogs are rare. The possible underlying mechanism in the dog and man is discussed.


Assuntos
Antipsicóticos/toxicidade , Fígado/efeitos dos fármacos , Porfirias Hepáticas/induzido quimicamente , Alanina Transaminase/sangue , Fosfatase Alcalina/sangue , Animais , Antipsicóticos/administração & dosagem , Bilirrubina/sangue , Coagulação Sanguínea/efeitos dos fármacos , Cães , Relação Dose-Resposta a Droga , Fezes/química , Feminino , Hiperplasia , Fígado/enzimologia , Fígado/patologia , Masculino , Tamanho do Órgão/efeitos dos fármacos , Tempo de Tromboplastina Parcial , Porfirias Hepáticas/metabolismo , Porfirias Hepáticas/patologia , Protoporfirinas/análise , Protoporfirinas/metabolismo , Timo/efeitos dos fármacos , Timo/patologia , Testes de Toxicidade
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa